HCA CFO granted 11,945 stock appreciation rights
HCA Healthcare EVP and CFO Mike A. Marks received a new equity award in the form of stock appreciation rights.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
HCA Healthcare EVP and CFO Mike A. Marks received a new equity award in the form of stock appreciation rights. On January 29, 2026, he was granted 11,945 stock appreciation rights tied to HCA common stock at an exercise price of $482.53 per share. These rights vest in four equal annual installments beginning January 29, 2027 and expire January 29, 2036. Following this grant, he beneficially holds 11,945 derivative securities directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Appreciation Right | 11,945 | $0.00 | $0.00 |
Footnotes (1)
- F1. The stock appreciation rights vest in four equal annual installments beginning on January 29, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did HCA (HCA) EVP and CFO Mike A. Marks receive?
When do Mike A. Marks’s new HCA (HCA) stock appreciation rights vest?
What is the exercise price and term of the new HCA (HCA) stock appreciation rights?
How many HCA (HCA) derivative securities does Mike A. Marks hold after this transaction?
Is the HCA (HCA) Form 4 for Mike A. Marks a stock sale or a grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.